Neuronal involvement in cisplatin neuropathy: Prospective clinical and neurophysiological studies

Brain

Volumn 130, Issue 4, 2007, Pages 1076-1088

  Krarup Hansen, A ^a   Helweg Larsen, S ^a   Schmalbruch, H ^b   Rorth M ^a   Krarup, C ^a,b,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Cisplatin neurotoxicity; Evoked potential; Nerve conduction; Neurophysiology; Testicular cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; HOFFMANN REFLEX; HUMAN; INNERVATION; MALE; MEDIAN NERVE; MYELINATION; NERVE CELL; NERVE CONDUCTION; NERVE FIBER; NERVE POTENTIAL; NEUROPHYSIOLOGY; PACINI CORPUSCLE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSORY NERVE; SENSORY NEUROPATHY; SPINAL GANGLION; SURAL NERVE; TEMPERATURE SENSE; TENDON REFLEX; TESTIS CANCER; TIBIAL NERVE; VIBRATION SENSE; ACTION POTENTIAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EMBRYONAL CARCINOMA; EVOKED SOMATOSENSORY RESPONSE; LONGITUDINAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PERCEPTIVE THRESHOLD; PHYSIOLOGY; REFLEX; SEMINOMA; SENSORY DYSFUNCTION; SENSORY NERVE CELL; TESTIS TUMOR; TOUCH;

ACTION POTENTIALS; ADULT; ANTINEOPLASTIC AGENTS; BLEOMYCIN; CARCINOMA, EMBRYONAL; CISPLATIN; ETOPOSIDE; EVOKED POTENTIALS, SOMATOSENSORY; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEURAL CONDUCTION; NEURONS, AFFERENT; PERIPHERAL NERVOUS SYSTEM DISEASES; PROSPECTIVE STUDIES; REFLEX; SEMINOMA; SENSATION DISORDERS; SENSORY THRESHOLDS; TESTICULAR NEOPLASMS; TOUCH;

EID: 34249651162     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl356     Document Type: Article

References (71)

1. Alberts DS, Noel JK. Cisplatin-associated neurotoxicity: can it be prevented? Anti-Cancer Drugs 1995; 6: 369-83.
2. Asbury AK. Sensory neuronopathy. Semin Neurol 1987; 7: 58-66.
3. Ashraf M, Riggs JE, Wearden S, Scotchel P. Prospective study of nerve conduction parameters and serum magnesium following cisplatin therapy. Gynecol Oncol 1990; 37: 29-33.
4. Baba M, Simonetti S, Krarup C. Sensory potentials evoked by tactile stimulation of different indentation velocities at the finger and palm. Muscle Nerve 2001; 24: 1213-8.
5. Bianchi R, Brines M, Lauria G, Savino C, Gilardini A, Nicolini G, et al. Protective effect of erythropoietin and its carbamylated derivative in experimental cisplatin peripheral neurotoxicity. Clin Cancer Res 2006; 12: 2607-12.
6. Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of longterm toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996; 14: 2923-32.
7. Boogerd W, Huinink WWtB, Dalesio O, Hoppenbrouwers WJJF, van der Sande JJ. Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. J Neurooncol 1990; 9: 255-63.
8. Bowers WJ, Chen X, Guo H, Frisina DR, Federoff HJ, Frisina RD. Neurotrophin-3 transduction attenuates cisplatin spiral ganglion neuron ototoxicity in the cochlea. Mol Ther 2002; 6: 12-8.
9. Buchthal F. Human nerve potentials evoked by tactile stimuli. I. Maximum conduction and properties of compound potentials. Acta Physiol Scand 1982a; 502: 5-18.
10. Buchthal F. Human nerve potentials evoked by tactile stimuli. II. Stimulus parameters and recruitment of components. Acta Physiol Scand 1982b; 502: 19-32.
11. Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol (Berl) 1992; 84: 364-71.
12. Cece R, Petruccioli MG, Cavaletti G, Barajon I, Tredici G. An ultrastructural study of neuronal changes in dorsal root ganglia (DRG) of rats after chronic cisplatin administrations. Histol Histopathol 1995; 10: 837-45.
13. Chaudhary UB, Haldas JR. Long-term complications of chemotherapy for germ cell tumours. Drugs 2003; 63: 1565-77.
14. Cowan JD, Kies MS, Roth JL, Joyce RP. Nerve conduction studies in patients treated with cis-diamminedichlorplatinum (II): a preliminary report. Cancer Treat Rep 1980; 64: 1119-22.
15. Daugaard G, Hansen HH, Rørth M. Treatment of malignant germ cell tumors. Ann Oncol 1990; 1: 196-202.
16. Daugaard GK, Petrera J, Trojaborg W. Electrophysiological study of the peripheral and central neurotoxic effects of cis-platin. Acta Neurol Scand 1987; 76: 86-93.
17. Dewar J, Lunt H, Abernethy DA, Dady P, Haas LF. Cisplatin neuropathy with Lhermitte's sign. J Neurol Neurosurg Psychiatry 1986; 49: 96-9.
18. Ewing DJ, Clarke BF. Diagnosis and management of diabetic autonomic neuropathy. BMJ 1982; 285: 916-8.
19. Fischer SJ, Podratz JL, Windebank AJ. Nerve growth factor rescue of cisplatin neurotoxicity is mediated through the high affinity receptor: studies in PC12 cells and p75 null mouse dorsal root ganglia. Neurosci Lett 2001; 308: 1-4.
20. Fowler CJ, Carroll MB, Burns D, Howe N, Robinson K. A portable system for measuring cutaneous thresholds for warming and cooling. J Neurol Neurosurg Psychiatry 1987; 50: 1211-5.
21. Gao WQ, Dybdal N, Shinsky N, Murnane A, Schmelzer C, Siegel M, et al. Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol 1995; 38: 30-7.
22. Gastaut JL, Pellisier JF. Cisplatin-induced neuropathy. A clinical, neurophysiological and pathological study. Rev Neurol (Paris) 1985; 141: 614-26.
23. Gill JS, Windebank AJ. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 1998; 101: 2842-50.
24. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 2001; 59: 657-63.
25. Gregg RW, Molepo JM, Monpetit VJA, Mikael NZ, Redmond D, Gadia M, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration, in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992; 10: 795-803.
26. Hadley D, Herr HW. Peripheral neuropathy associated with cisdichlorodiammineplatinum (II) treatment. Cancer 1979; 44: 2026-8.
27. Hansen SW. Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer. BMJ 1990; 300: 511-2.
28. Hansen SW, Helweg-Larsen S, Trojaborg W. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol 1989; 7: 1457-61.
29. Hartmann JT, Kollmannsberger C, Kanz L, Bokemeyer C. Platinum organ toxicity and possible prevention in patients with testicular cancer. Int J Cancer 1999; 83: 866-9.
30. Horowitz SH, Krarup C. Conduction studies of the normal sural nerve. Muscle Nerve 1992; 15: 374-83.
31. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
32. Jordan P, Carmo-Fonseca M. Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 2000; 57: 1229-35.
33. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res 2001; 478: 23-43.
34. Kelland LR. Preclinical perspectives on platinum resistance. Drugs 2000; 59 (Suppl 4): 1-8.
35. Krarup C. Compound sensory action potential in normal and pathological human nerves. Muscle Nerve 2004; 29: 465-83.
36. Krarup C, Trojaborg W. Compound sensory action potentials evoked by tactile and by electrical stimulation in normal median and sural nerves. Muscle Nerve 1994; 17: 733-40.
37. Krarup C, Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rørth M. Electrophysiological prospective studies including responses to tactile stimulation in cisplatin induced neuropathy. Clin Neurophysiol 2005, p. 93.
38. Krarup-Hansen A, Fugleholm K, Helweg-Larsen S, Hauge EN, Schmalbruch H, Trojaborg W, et al. Examination of distal involvement in cisplatin-induced neuropathy in man. An electrophysiological and histological study with particular reference to touch receptor function. Brain 1993; 116: 1017-41.
39. Krarup-Hansen A, Rietz B, Krarup C, Heydorn K, Rorth M, Schmalbruch H. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropathol Appl Neurobiol 1999; 25: 29-40.
40. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rørth M, Krarup C. Localization of the axonal lesion in cisplatin induced neuropathy in testicular cancer. J Neurol 2004; 251: 36.
41. Lippard SJ. New chemistry of an old molecule: cis-[Pt(NH3)2Cl2]. Science 1982; 218: 1075-82.
42. Loewenstein WR. Mechano-electric transduction in the Pacinian corpuscle. Initiation of sensory impulses in mechanoreceptors, Berlin: Springer-Verlag; 1971. p. 269.
43. McDonald ES, Windebank AJ. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis 2002; 9: 220-33.
44. McDonald ES, Randon KR, Knight A, Windebank AJ. Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis 2005; 18: 305-13.
45. McLeod JG. Paraneoplastic neuropathies. In: Dyck PJ, Thomas PK, Griffin JW, Low PA, Poduslo JF. editors. Peripheral neuropathy. Philadelphia: W.B. Saunders; 1993. p. 1583-90.
46. McLeod JG, Tuck RR, Pollard JD, Cameron J, Walsh JC. Chronic polyneuropathy of undetermined cause. J Neurol Neurosurg Psychiatry 1984; 47: 530-5.
47. Mountcastle VB, Lamotte RH, Carli G. Detection thresholds for stimuli in humans and monkeys: comparison with threshold events in mechanoreceptive afferent nerve fibers innervating the monkey hand. J Neurophysiol 1972; 35: 122-36.
48. Nielsen VK. The peripheral nerve function in chronic renal failure. IV. An analysis of the vibratory perception threshold. Acta Med Scand 1972; 191: 287-96.
49. Pedersen L, Trojaborg W. Visual, auditory and somatosensory pathway involvement in hereditary cerebellar ataxia, Friedreich's ataxia and familial spastic paraplegia. Electroencephalogr. Clin Neurophysiol 1981; 52: 283-97.
50. Peltier AC, Russell JW. Recent advances in drug-induced neuropathies. Curr Opin Neurol 2002; 15: 633-8.
51. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Ann Oncol 2000; 11: 509-13.
52. Quasthoff S, Hartung H-P. Chemotherapy-induced peripheral neuropathy. J Neurol 2002; 249: 9-17.
53. Roelofs RI, Hrushesky W, Rogin J, Rosenberg L. Peripheral sensory neuropathy and cisplatin chemotherapy. Neurology 1984; 34: 934-8.
54. Rosenfalck P, Rosenfalck A. Electromyography - sensory and motor conduction. Findings in normal subjects. Copenhagen: Laboratory of Clinical Neurophysiology, Rigshospitalet; 1975.
55. Rosenfeld CS, Broder LE. Cisplatin-induced autonomic neuropathy. Cancer Treat Rep 1984; 68: 659-60.
56. Schaumburg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, et al. Sensory neuropathy from pyridoxine abuse. A new megavitamine syndrome. N Engl J Med 1983; 309: 445-8.
57. Sghirlanzoni A, Pareyson D, Lauria G. Sensory neuron diseases. Lancet Neurol 2005; 4: 349-61.
58. Simonetti S, Dahl K, Krarup C. Different indentation velocities activate different populations of mechanoreceptors in humans. Muscle Nerve 1998; 21: 858-68.
59. Smitt PS, Posner JB. Paraneoplastic peripheral neuropathy. In: Latov N, Wokke JHJ, Kelly JJ. editors. Immunological and infectious diseases of the peripheral nerves. Cambridge: Cambridge University Press; 1998. p. 208-24.
60. Sumner AJ. Axonal polyneuropathies. Philadelphia: Saunders; 1980. p. 340-57.
61. Sumner AJ, Asbury AK. Physiological studies of the dying-back phenomenon. Muscle stretch afferents in acrylamide neuropathy. Brain 1975; 98: 91-100.
62. Thompson SW, Davis LE, Kornfeld M, Hilgers RD, Standefer JC. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984; 54: 1269-75.
63. Tomiwa K, Nolan C, Cavanagh JB. The effects of cisplatin on rat spinal ganglia: a study by light and electron microscopy and by morphometry. Acta Neuropathol (Berl) 1986; 69: 295-308.
64. Trojaborg W, Petersen E. Visual and somatosensory evoked cortical potentials in multiple sclerosis. J Neurol Neurosurg Psychiatry 1979; 42: 323-30.
65. Trojaborg W, Moon A, Andersen A, Andersen BB, Trojaborg NS. Sural nerve conduction parameters in normal subjects related to age, gender, temperature, and height: a reappraisal. Muscle Nerve 1992; 15: 666-71.
66. Walsh TJ, Clark AW, Parhad IM, Green WR. Neurotoxic effects of cisplatin therapy. Arch Neurol 1982; 39: 719-20.
67. Windebank AJ. Chemotherapeutic neuropathy. Curr Opin Neurol 1999; 12: 565-71.
68. Windebank AJ, Low PA, Blexrud MD, Schmelzer JD, Schaumburg HH. Pyridoxine neuropathy in rats: specific degeneration of sensory axons. Neurology 1985; 35: 1617-22.
69. Windebank AJ, Smith AG, Russell JW. The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurology 1994; 44: 488-94.
70. Xu Y, Sladky JT, Brown MJ. Dose-dependent expression of neuronopathy after experimental pyridoxine intoxication. Neurology 1989; 39: 1077-83.
71. Zheng JL, Stewart RR, Gao WQ. Neurotrophin-4/5 enhances survival of cultured spiral ganglion neurons and protects them from cisplatin neurotoxicity. J Neurosci 1995; 15: 5079-87.